21st Century Cures Act - Beau Biden Cancer Moonshot
CFDA 93.353 · Federal Grants & Funding
Total Funding
$839.1M
Awards
168
Recipients
81
States
31
Last Updated
Mar 20, 2026
Yearly Funding Trend
| Fiscal Year | Obligations | Awards | YoY Change |
|---|---|---|---|
| 2024 | $616.1M | 119 | |
| 2025 | $211.7M | 44 | -65.6% |
| 2026 | $11.2M | 5 | -94.7% |
Award Type Mix
| Type | Obligations | Awards |
|---|---|---|
| $0 | 0 |
Top 50 Awards under CFDA 93.353
Largest individual obligations for 21st Century Cures Act - Beau Biden Cancer Moonshot.
| Award | Recipient | Awarding Agency | Place | FY | Obligation |
|---|---|---|---|---|---|
ASST_NON_U24CA233243_075 HUMAN TUMOR ATLAS NETWORK: DATA COORDINATING CENTER - PROJECT SUMMARY/ABSTRACT THE HUMAN TUMOR ATLAS NETWORK (HTAN) SEEKS TO IMPROVE OUR UNDERSTANDING OF THE IMPORTANT TRANSITIONS… | DANA-FARBER CANCER INSTITUTE, INC. Massachusetts | Department of Health and Human Services National Institutes of Health | MA-90 | 2024 | $28,562,644 |
ASST_NON_U24CA224319_075 HIGH-DIMENSIONAL IMMUNE MONITORING OF NCI-SUPPORTED IMMUNOTHERAPY TRIALS - SUMMARY DEFINING WHO IS LIKELY TO RESPOND TO CANCER IMMUNOTHERAPY AND WHO MAY NOT BENEFIT, DUE TO PRIMAR… | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI New York | Department of Health and Human Services National Institutes of Health | NEW YORK, NY-13 | 2024 | $20,178,293 |
ASST_NON_U24CA224309_075 STANFORD CANCER IMMUNE MONITORING AND ANALYSIS CENTER (CIMAC) - ABSTRACT FOR THIS CIMAC RENEWAL, THE STANFORD CANCER IMMUNE MONITORING AND ANALYSIS CENTER (CIMAC) WILL CONTINUE TO… | THE LELAND STANFORD JUNIOR UNIVERSITY California | Department of Health and Human Services National Institutes of Health | PALO ALTO, CA-16 | 2024 | $18,162,009 |
ASST_NON_P01CA154303_075 PROTEIN KINASE THERAPEUTIC TARGETS FOR NON-SMALL CELL LUNG CARCINOMA - LUNG CANCER IS THE LEADING CAUSE OF CANCER DEATH IN THE UNITED STATES AND WORLD-WIDE, WITH OVER 85% OF CASES… | DANA-FARBER CANCER INSTITUTE, INC. Massachusetts | Department of Health and Human Services National Institutes of Health | BOSTON, MA-07 | 2024 | $17,803,632 |
ASST_NON_U19CA214253_075 RESEARCH ON PROSTATE CANCER IN MEN OF AFRICAN ANCESTRY: DEFINING THE ROLES OF GENETICS, IMMUNITY AND STRESS (RESPOND) - AFRICAN-AMERICAN (AA) MEN EXPERIENCE THE HIGHEST PROSTATE C… | UNIVERSITY OF SOUTHERN CALIFORNIA California | Department of Health and Human Services National Institutes of Health | LOS ANGELES, CA-34 | 2024 | $16,840,150 |
ASST_NON_U24CA224285_075 MD ANDERSON CANCER IMMUNE MONITORING AND ANALYSIS CENTER MDA-CIMAC - ABSTRACT IMMUNOTHERAPY (IMT) HAS EMERGED AS A PROMISING TREATMENT STRATEGY ACROSS A BROAD SPECTRUM OF HUMAN CA… | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER Texas | Department of Health and Human Services National Institutes of Health | HOUSTON, TX-09 | 2024 | $16,682,682 |
ASST_NON_U2CCA252971_075 USC PE-GCS: OPTIMIZING ENGAGEMENT OF HISPANIC COLORECTAL CANCER PATIENTS IN CANCER GENOMIC CHARACTERIZATION STUDIES - COLORECTAL CANCER (CRC) IS THE SECOND LEADING CAUSE OF CANCER… | UNIVERSITY OF SOUTHERN CALIFORNIA California | Department of Health and Human Services National Institutes of Health | LOS ANGELES, CA-34 | 2024 | $16,634,214 |
ASST_NON_U2CCA252974_075 COUNT ME IN: PARTNERING WITH PATIENTS TO DEFINE THE CLINICAL AND GENOMIC LANDSCAPE OF RARE AGGRESSIVE SARCOMAS IN CHILDREN AND ADULTS - OSTEOSARCOMA (OS) AND LEIOMYOSARCOMA (LMS)… | THE BROAD INSTITUTE, INC Massachusetts | Department of Health and Human Services National Institutes of Health | CAMBRIDGE, MA-07 | 2024 | $16,622,112 |
ASST_NON_U24CA224331_075 CANCER IMMUNE MONITORING AND ANALYSIS CENTER - SUMMARY BECAUSE CANCER IMMUNOTHERAPY CONSTITUTES ONE OF THE MOST TRANSFORMATIVE THERAPEUTIC MOVEMENTS OVER THE HISTORY OF CANCER TRE… | DANA-FARBER CANCER INSTITUTE, INC. Massachusetts | Department of Health and Human Services National Institutes of Health | BOSTON, MA-07 | 2024 | $16,455,371 |
ASST_NON_U2CCA252973_075 ENGAGEMENT OF AMERICAN INDIANS OF SOUTHWESTERN TRIBAL NATIONS IN CANCER GENOME SEQUENCING - WHILE SOVEREIGN AMERICAN INDIAN AND ALASKAN NATIVE (AI/AN) TRIBES AND COMMUNITIES ACROS… | UNIVERSITY OF NEW MEXICO New Mexico | Department of Health and Human Services National Institutes of Health | NM-90 | 2024 | $16,231,787 |
ASST_NON_U2CCA252981_075 WASHINGTON UNIVERSITY PARTICIPANT ENGAGEMENT AND CANCER GENOMIC SEQUENCING CENTER (WU-PE-CGS) - PARTICIPANT ENGAGEMENT AND GENOMIC SEQUENCING RESEARCH FROM THE WASHINGTON UNIVERSI… | WASHINGTON UNIVERSITY, THE Missouri | Department of Health and Human Services National Institutes of Health | SAINT LOUIS, MO-01 | 2024 | $14,340,941 |
ASST_NON_U2CCA233195_075 THE CELLULAR GEOGRAPHY OF THERAPEUTIC RESISTANCE IN CANCER - MOST PATIENTS WHO DIE FROM CANCER DO SO BECAUSE THEIR CANCER IS RESISTANT TO AVAILABLE THERAPIES, EITHER INTRINSICALLY… | DANA-FARBER CANCER INSTITUTE, INC. Massachusetts | Department of Health and Human Services National Institutes of Health | BOSTON, MA-07 | 2024 | $13,576,522 |
ASST_NON_U54CA232568_075 DISCOVERY AND DEVELOPMENT OF OPTIMAL IMMUNOTHERAPEUTIC STRATEGIES FOR CHILDHOOD CANCERS - OVERALL SUMMARY/ABSTRACT THERE IS A MAJOR PARADOX CONFRONTING THE FIELD OF CHILDHOOD CAN… | THE CHILDREN'S HOSPITAL OF PHILADELPHIA Pennsylvania | Department of Health and Human Services National Institutes of Health | PA-90 | 2025 | $13,073,531 |
ASST_NON_U2CCA233285_075 CENTER FOR PEDIATRIC TUMOR CELL ATLAS - PROJECT SUMMARY - OVERALL CHILDHOOD CANCER IS THE SECOND MOST COMMON CAUSES OF CHILDHOOD DEATHS. CANCERS IN CHILDREN ARE HIGHLY DISTINCT FR… | THE CHILDREN'S HOSPITAL OF PHILADELPHIA Pennsylvania | Department of Health and Human Services National Institutes of Health | PA-90 | 2024 | $12,810,840 |
ASST_NON_U2CCA233284_075 TRANSITION TO METASTATIC STATE: LUNG CANCER, PANCREATIC CANCER AND BRAIN METASTASIS - PROJECT SUMMARY (OVERALL UNIT) METASTASIS EMBODIES THE DYNAMIC, COMPLEX, WHOLE-ORGANISM PATHO… | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH New York | Department of Health and Human Services National Institutes of Health | NY-90 | 2025 | $12,355,800 |
ASST_NON_P50CA244433_075 THE IMPLEMENTATION SCIENCE CENTER FOR CANCER CONTROL EQUITY - ABSTRACT - OVERALL AFTER DECADES OF RESEARCH DEVELOPING AND TESTING INTERVENTIONS FOR CANCER CONTROL, WE HAVE THE EVI… | PRESIDENT AND FELLOWS OF HARVARD COLLEGE Massachusetts | Department of Health and Human Services National Institutes of Health | MA-90 | 2025 | $12,088,106 |
ASST_NON_U54CA232561_075 NOVEL IMMUNOMODULATION AND FACILITATION OF “SUPPRESSION PROOF” CAR NK CELL AGAINST EWING SARCOMA - OVERALL CENTER ABSTRACT THIS APPLICATION DESCRIBES THE PEDIATRIC OHIO-NEW YORK C… | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL Ohio | Department of Health and Human Services National Institutes of Health | OH-90 | 2025 | $12,062,912 |
ASST_NON_U2CCA233311_075 PRECANCER ATLAS OF FAMILIAL ADENOMATOUS POLYPOSIS - COLORECTAL CANCER (CRC) IS THE THIRD HIGHEST CAUSE OF CANCER DEATH IN THE UNITED STATES. ALMOST 80% OF SPORADIC COLORECTAL CANC… | THE LELAND STANFORD JUNIOR UNIVERSITY California | Department of Health and Human Services National Institutes of Health | STANFORD, CA-16 | 2025 | $11,608,138 |
ASST_NON_P01CA210944_075 RADIATION AND CHECKPOINT BLOCKADE FOR CANCER IMMUNE THERAPY - THE LONG-TERM GOAL OF THIS P01 IS TO UNDERSTAND THE INTERSECTION OF RADIATION BIOLOGY AND CANCER IMMUNOLOGY AND TO TR… | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE Pennsylvania | Department of Health and Human Services National Institutes of Health | PHILADELPHIA, PA-03 | 2024 | $11,395,739 |
ASST_NON_U2CCA233254_075 BREAST PRE-CANCER ATLAS CENTER - ABSTRACT – OVERALL DEVELOPMENT OF INVASIVE BREAST CANCER MAY FREQUENTLY PROGRESS THROUGH A PREINVASIVE PRECURSOR CALLED DUCTAL CARCINOMA IN SITU (… | DUKE UNIVERSITY North Carolina | Department of Health and Human Services National Institutes of Health | NC-90 | 2025 | $11,388,422 |
ASST_NON_U2CCA252979_075 OPTIMIZING ENGAGEMENT IN DISCOVERY OF MOLECULAR EVOLUTION OF LOW GRADE GLIOMA (OPTIMUM) - PROJECT SUMMARY LOWER GRADE (WORLD HEALTH ORGANIZATION (WHO) GRADE II/III) GLIOMA (LGG),… | YALE UNIV Connecticut | Department of Health and Human Services National Institutes of Health | NEW HAVEN, CT-03 | 2024 | $10,929,171 |
ASST_NON_U54CA243124_075 EXPERIMENTAL AND PRECLINICAL MODELING OF NUP98-REARRANGED ACUTE LEUKEMIA - PROJECT SUMMARY - OVERVIEW FUSION ONCOPROTEINS (FO) ARISING FROM THE REARRANGEMENT OF NUCLEOPORIN 98 (NU… | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC Tennessee | Department of Health and Human Services National Institutes of Health | MEMPHIS, TN-09 | 2025 | $10,455,473 |
ASST_NON_U54CA231649_075 TARGETING EWSR1-FLI1 THROUGH FUNCTIONAL, STRUCTURAL AND CHEMICAL APPROACHES - EWING SARCOMA IS THE SECOND MOST COMMON BONE AND SOFT TISSUE MALIGNANCY IN CHILDREN AND ADOLESCENTS.… | THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER Texas | Department of Health and Human Services National Institutes of Health | DALLAS, TX-30 | 2024 | $10,042,149 |
ASST_NON_U2CCA233280_075 OMIC AND MULTIDIMENSIONAL SPATIAL ATLAS OF METASTATIC BREAST AND PROSTATE CANCERS - ABSTRACT - OVERALL WE PROPOSE TO CREATE AN OMIC AND MULTIDIMENSIONAL SPATIAL (OMS) ATLAS THAT W… | OREGON HEALTH & SCIENCE UNIVERSITY Oregon | Department of Health and Human Services National Institutes of Health | OR-90 | 2024 | $9,713,626 |
ASST_NON_UM1CA233080_075 SIMPRO RESEARCH CENTER: INTEGRATION AND IMPLEMENTATION OF PROS FOR SYMPTOM MANAGEMENT IN ONCOLOGY PRACTICE - PROJECT SUMMARY IN 2018, MORE THAN 1.7 MILLION AMERICANS WILL RECEIVE… | DANA-FARBER CANCER INSTITUTE, INC. Massachusetts | Department of Health and Human Services National Institutes of Health | BOSTON, MA-07 | 2025 | $9,045,978 |
ASST_NON_R01DA047952_075 INCREASING ACCESS TO HEPATITIS C TREATMENT IN OPIOID ENDEMIC RURAL AREAS: THE KENTUCKY VIRAL HEPATITIS TREATMENT (KEY TREAT) STUDY - ABSTRACT THE OVERARCHING GOAL OF THE KENTUCKY… | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE Kentucky | Department of Health and Human Services National Institutes of Health | KY-90 | 2024 | $8,741,791 |
ASST_NON_UM1CA233033_075 ENHANCED, EHR-FACILITATED CANCER SYMPTOM CONTROL (E2C2) PRAGMATIC CLINICAL TRIAL - CANCER AND ITS TREATMENT ENGENDER DISABLING SYMPTOMS THAT ARE FREQUENTLY UNDERTREATED, AND ASSOC… | MAYO CLINIC Minnesota | Department of Health and Human Services National Institutes of Health | ROCHESTER, MN-01 | 2024 | $8,698,201 |
ASST_NON_U2CCA233262_075 PRE-CANCER ATLASES OF CUTANEOUS AND HEMATOLOGIC ORIGIN (PATCH CENTER) - SUMMARY-ABSTRACT THE OVERALL GOAL OF THIS PROPOSAL IS TO CONSTRUCT TWO PRE-CANCER ATLASES (PCAS) FROM HIGH… | PRESIDENT AND FELLOWS OF HARVARD COLLEGE Massachusetts | Department of Health and Human Services National Institutes of Health | MA-90 | 2025 | $8,650,768 |
ASST_NON_U2CCA233303_075 WASHINGTON UNIVERSITY HUMAN TUMOR ATLAS RESEARCH CENTER - PROJECT SUMMARY/ABSTRACT: OVERALL DIVERSE AREAS OF CANCER RESEARCH HAVE PROGRESSED TO THE POINT THAT IT IS NOW FEASIBLE T… | WASHINGTON UNIVERSITY, THE Missouri | Department of Health and Human Services National Institutes of Health | SAINT LOUIS, MO-01 | 2025 | $7,849,641 |
ASST_NON_U54CA224065_075 UNIVERSITY OF TEXAS PDX DEVELOPMENT AND TRIAL CENTER - SUMMARY OUR OVERARCHING GOAL FOR THE UNIVERSITY TEXAS PDX DEVELOPMENT AND TRIAL CENTER (UTPDTC) IS TO OPTIMIZE PERSONALIZED… | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER Texas | Department of Health and Human Services National Institutes of Health | HOUSTON, TX-09 | 2024 | $7,465,372 |
ASST_NON_P50CA244289_075 BUILDING RESEARCH IN IMPLEMENTATION AND DISSEMINATION TO CLOSE GAPS AND ACHIEVE EQUITY IN CANCER CONTROL (BRIDGE-C2) CENTER - OVERALL PROJECT SUMMARY THE BUILDING RESEARCH IN IMPL… | OREGON HEALTH & SCIENCE UNIVERSITY Oregon | Department of Health and Human Services National Institutes of Health | OR-90 | 2025 | $7,463,834 |
ASST_NON_U54CA244711_075 ENGINEERING THE NEXT GENERATION OF T CELLS - OVERALL SUMMARY THIS U54 “IMMUNO-ENGINEERING TO IMPROVE IMMUNOTHERAPY (I3) CENTER” WAS DEVELOPED IN RESPONSE TO RFA-CA-19-013. THE PUR… | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE Pennsylvania | Department of Health and Human Services National Institutes of Health | PA-90 | 2025 | $7,101,772 |
ASST_NON_U54CA224079_075 THE MSKCC-UW/FRED HUTCH PROSTATE CANCER DRUG RESISTANCE AND SENSITIVITY CENTER - OVERALL ABSTRACT THE LETHAL STAGE OF METASTATIC PROSTATE CANCER, CALLED CASTRATION RESISTANT PROST… | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH New York | Department of Health and Human Services National Institutes of Health | NEW YORK, NY-12 | 2024 | $6,788,864 |
ASST_NON_U24CA224316_075 CANCER IMMUNOLOGIC DATA COMMONS (CIDC) SUPPLEMENT REQUEST - ABSTRACT CANCER IMMUNOTHERAPIES HAVE EMERGED AS HIGHLY PROMISING APPROACHES TO TREAT CANCER PATIENTS, PARTICULARLY SINC… | DANA-FARBER CANCER INSTITUTE, INC. Massachusetts | Department of Health and Human Services National Institutes of Health | BOSTON, MA-07 | 2024 | $6,785,000 |
ASST_NON_U54CA233306_075 UNIVERSITY OF CALIFORNIA MINORITY PATIENT-DERIVED XENOGRAFT (PDX) DEVELOPMENT AND TRIAL CENTER (UCAMP) TO REDUCE CANCER HEALTH DISPARITIES - OVERALL UNIVERSITY OF CALIFORNIA MINOR… | UNIVERSITY OF CALIFORNIA, DAVIS California | Department of Health and Human Services National Institutes of Health | CA-90 | 2024 | $6,654,662 |
ASST_NON_U54CA231630_075 DEFINING AND TARGETING THE MOLECULAR VULNERABILITIES OF THE PAX3-FOXO1 PROTEIN IN RHABDOMYOSARCOMA - ABSTRACT – OVERALL (REVISED) FUSION-POSITIVE ALVEOLAR RHABDOMYOSARCOMA (ARMS)… | DUKE UNIVERSITY North Carolina | Department of Health and Human Services National Institutes of Health | DURHAM, NC-04 | 2024 | $6,477,113 |
ASST_NON_U54CA243125_075 BIOLOGY AND THERAPY OF C11ORF95-RELA FUSION-DRIVEN EPENDYMOMA - ABSTRACT/SUMMARY – OVERALL (HOLLAND) DUE TO A CHROMOTHRIPSIS EVENT ON CHROMOSOME 11, THE MAJORITY OF SUPRATENTORIAL… | FRED HUTCHINSON CANCER CENTER Washington | Department of Health and Human Services National Institutes of Health | WA-90 | 2024 | $6,164,669 |
ASST_NON_U54CA231641_075 AN INTEGRATED APPROACH TO ANALYZE AND TARGET EWS/FLI IN EWING SARCOMA - OVERALL SECTION SUMMARY/ABSTRACT THE OVERARCHING GOAL OF OUR FUSONC2 TEST (TARGETING THE EWING SARCOMA TRAN… | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL Ohio | Department of Health and Human Services National Institutes of Health | OH-90 | 2024 | $6,163,485 |
ASST_NON_U54CA224018_075 OVERCOMING DRUG RESISTANCE IN MULTIPLE MYELOMA - THIS SUPPLEMENT WILL ALLOW THE MAYO CLINIC/UNIVERSITY OF MINNESOTA MYELOMA DRSC TO PROVIDE UNIQUE RESOURCES AND SUPPORT TO DR. CON… | MAYO CLINIC ARIZONA Arizona | Department of Health and Human Services National Institutes of Health | SCOTTSDALE, AZ-01 | 2024 | $5,994,141 |
ASST_NON_U54CA231638_075 THE CENTER FOR SYNOVIAL SARCOMA BIOLOGY AND THERAPEUTICS - THE CENTER FOR SYNOVIAL SARCOMA BIOLOGY AND THERAPEUTICS ABSTRACT THE OVERARCHING GOAL OF THIS FUSONC2 CENTER FOR SYNO… | DANA-FARBER CANCER INSTITUTE, INC. Massachusetts | Department of Health and Human Services National Institutes of Health | BOSTON, MA-07 | 2024 | $5,788,705 |
ASST_NON_U01CA294552_075 PEDIATRIC SOLID TUMOR MICROENVIRONMENT ATLAS - OVERALL SUMMARY/ABSTRACT THE MAJORITY OF SOLID TUMORS IN CHILDREN HAVE A UNIQUE ORIGIN COMPARED TO THOSE IN ADULTS, STEMMING FROM TH… | CHILDREN'S HOSPITAL LOS ANGELES California | Department of Health and Human Services National Institutes of Health | CA-90 | 2024 | $5,678,350 |
ASST_NON_U01CA294507_075 MYELOMA MULTIDIMENSIONAL PRECANCER ATLAS - SUMMARY MULTIPLE MYELOMA (MM) IS ALMOST ALWAYS PRECEDED BY MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS) AND SMOLDERING MYEL… | DANA-FARBER CANCER INSTITUTE, INC. Massachusetts | Department of Health and Human Services National Institutes of Health | MA-90 | 2024 | $5,566,942 |
ASST_NON_U01CA232826_075 LEVERAGING AN ELECTRONIC MEDICAL RECORD INFRASTRUCTURE TO IDENTIFY PRIMARY CARE PATIENTS ELIGIBLE FOR GENETIC TESTING FOR HEREDITARY CANCER AND EVALUATE NOVEL CANCER GENETICS SERV… | UNIVERSITY OF UTAH Utah | Department of Health and Human Services National Institutes of Health | UT-90 | 2024 | $5,468,625 |
ASST_NON_U54CA243126_075 CENTER FOR THERAPEUTIC TARGETING OF THE FUSION ONCOPROTEIN OF FIBROLAMELLAR HEPATOCELLULAR CARCINOMA - PROJECT SUMMARY / ABSTRACT FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC) IS A… | ROCKEFELLER UNIVERSITY New York | Department of Health and Human Services National Institutes of Health | NEW YORK, NY-12 | 2024 | $5,377,875 |
ASST_NON_U01CA294551_075 UNDERSTANDING THE ROLE OF TUMOR MICROENVIRONMENT IN LOW GRADE GLIOMA PROGRESSION TO MALIGNANCY - ABSTRACT OUR PCA RESEARCH CENTER BRINGS TOGETHER THE UCLA NEUROSURGERY TEAM WITH T… | CALIFORNIA INSTITUTE OF TECHNOLOGY California | Department of Health and Human Services National Institutes of Health | CA-90 | 2024 | $5,275,940 |
ASST_NON_U01CA294536_075 PRE-CANCER ATLAS OF SKIN CANCER - THE OVERARCHING GOAL OF OUR PROPOSAL IS TO DEVELOP A PRE-CANCER ATLAS OF SKIN CANCER. SKIN IS AN IDEAL MODEL TO STUDY THE EARLY PHASES OF TUMORIG… | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE California | Department of Health and Human Services National Institutes of Health | CA-90 | 2024 | $5,182,743 |
ASST_NON_U01CA294532_075 HUMAN PROSTATE TUMOR ATLAS CENTER - PROJECT SUMMARY EARLIER GAINS IN REDUCING PROSTATE CANCER (PCA) MORTALITY, PARTIALLY DUE TO ADVANCES IN SCREENING AND THE USE OF ANDROGEN DEPRI… | WASHINGTON UNIVERSITY, THE Missouri | Department of Health and Human Services National Institutes of Health | MO-90 | 2024 | $5,162,603 |
ASST_NON_U01CA294527_075 A MULTIMODAL 3D ATLAS OF COLORECTAL CANCER ACROSS AGES OF ONSET - PROJECT SUMMARY WE PROPOSE THE CONSTRUCTION OF A THREE-DIMENSIONAL (3D) MULTIMODAL MOLECULAR ATLAS OF COLORECTAL… | VANDERBILT UNIVERSITY Tennessee | Department of Health and Human Services National Institutes of Health | NASHVILLE, TN-05 | 2024 | $5,159,940 |
ASST_NON_U01CA294518_075 CENTER FOR GASTRIC PRE-CANCER ATLAS OF MULTIDIMENSIONAL EVOLUTION IN 3D (GAME3D) - PROJECT SUMMARY THIS APPLICATION AIMS TO ADDRESS THE URGENT NEED FOR PRECISION IN INTERCEPTING H… | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER Texas | Department of Health and Human Services National Institutes of Health | TX-90 | 2024 | $5,158,661 |
ASST_NON_UH3CA233229_075 ACCISIS-CHICAGO - PROJECT SUMMARY SCREENING FOR COLORECTAL CANCER (CRC) NOT ONLY DETECTS DISEASE EARLY BUT ALSO PREVENTS CANCER BY FINDING AND REMOVING PRECANCEROUS POLYPS. THE OV… | UNIVERSITY OF CHICAGO Illinois | Department of Health and Human Services National Institutes of Health | IL-90 | 2024 | $5,138,482 |
Top 50 awards shown, ranked by obligated amount. Dates reflect performance period; last-modified dates match USAspending.gov. Complete listings include all transaction history going back to FY2024.
Spending by State
| State | Funding | Awards |
|---|---|---|
| Massachusetts | $180.8M | 25 |
| California | $128.3M | 22 |
| Pennsylvania | $79.0M | 16 |
| New York | $71.7M | 14 |
| Texas | $43.7M | 7 |
| North Carolina | $36.4M | 7 |
| Missouri | $33.6M | 7 |
| Oregon | $28.5M | 6 |
| Washington | $27.9M | 9 |
| Ohio | $25.5M | 5 |
| Tennessee | $24.1M | 5 |
| Connecticut | $19.9M | 3 |
| New Mexico | $16.2M | 1 |
| Kentucky | $15.2M | 3 |
| Colorado | $15.0M | 5 |
| Minnesota | $14.2M | 4 |
| Michigan | $11.2M | 4 |
| Maryland | $8.3M | 3 |
| Illinois | $7.9M | 3 |
| Alabama | $7.1M | 2 |
| Wisconsin | $6.9M | 2 |
| Utah | $6.7M | 2 |
| Florida | $6.1M | 4 |
| Arizona | $6.0M | 1 |
| South Carolina | $5.3M | 2 |
| Iowa | $4.5M | 1 |
| Indiana | $3.9M | 1 |
| District of Columbia | $3.2M | 1 |
| Rhode Island | $1.1M | 1 |
| New Hampshire | $437K | 1 |
| New Jersey | $400K | 1 |
Top Recipients
Agencies Administering This Program
Source: USAspending.gov · All Programs